Wellington Management Group LLP Buys Shares of 2,949,734 Definium Therapeutics, Inc. $DFTX

Wellington Management Group LLP purchased a new position in Definium Therapeutics, Inc. (NASDAQ:DFTX) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 2,949,734 shares of the company’s stock, valued at approximately $138,755,000. Wellington Management Group LLP owned 2.20% of Definium Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Royal Bank of Canada increased its position in Definium Therapeutics by 10.4% during the first quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock worth $382,000 after acquiring an additional 6,148 shares during the period. Creative Planning boosted its holdings in Definium Therapeutics by 2.6% in the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after purchasing an additional 1,655 shares during the period. JPMorgan Chase & Co. grew its position in Definium Therapeutics by 5.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company’s stock worth $315,000 after purchasing an additional 2,342 shares during the last quarter. Rhumbline Advisers grew its position in Definium Therapeutics by 6.3% in the 2nd quarter. Rhumbline Advisers now owns 115,296 shares of the company’s stock worth $748,000 after purchasing an additional 6,839 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in shares of Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after purchasing an additional 2,003 shares during the period. Institutional investors and hedge funds own 27.91% of the company’s stock.

Definium Therapeutics Price Performance

Shares of Definium Therapeutics stock opened at $39.72 on Tuesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95. The firm’s 50-day simple moving average is $43.99 and its 200-day simple moving average is $28.96. Definium Therapeutics, Inc. has a twelve month low of $8.70 and a twelve month high of $49.70. The firm has a market cap of $5.34 billion, a P/E ratio of -11.58 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.89). As a group, research analysts expect that Definium Therapeutics, Inc. will post -3.02 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Matthew T. Wiley sold 2,867 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $129,101.01. Following the sale, the insider directly owned 174,633 shares in the company, valued at approximately $7,863,723.99. This represents a 1.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Mark Sullivan sold 13,008 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $585,750.24. Following the completion of the transaction, the insider directly owned 320,571 shares of the company’s stock, valued at approximately $14,435,312.13. The trade was a 3.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 48,096 shares of company stock valued at $2,165,763. 2.40% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

DFTX has been the topic of a number of recent research reports. Maxim Group set a $55.00 target price on Definium Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 14th. JonesTrading upped their price target on Definium Therapeutics from $74.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, August 13th. Canaccord Genuity Group set a $64.00 price objective on Definium Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 13th. Needham & Company LLC lifted their price objective on Definium Therapeutics from $50.00 to $66.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $63.00.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.